High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential

Hepatology

Volumn 32, Issue 1, 2000, Pages 43-48

  Wang, Lu ^a   Tang, Zhao You ^a   Qin, Lun Xiu ^a   Wu, Xiao Feng ^a   Sun, Hui Chuan ^a   Xue, Qiong ^a   Ye, Sheng Long ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; GROWTH INHIBITION; LIFESPAN; LIVER CELL CARCINOMA; LONG TERM CARE; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME; XENOGRAFT;

EID: 0034235785     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.8525     Document Type: Article

References (38)

1. 1. Parkin DM, Pisani P, Ferlay J. Estimates of worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
2. 2. Kuroishi T, Hayakawa N, Kurihara M, Aoki K. Cancer mortality in 33 countries of the world (1953-1987). In: Tominaga S, Fujimoto I, Kuraihara M, eds. Cancer mortality and morbidity statistics (Japan and the world 1994). Tokyo: Jpn Sci Soc Press, 1994;167-230.
3. 3. Li LD, Zhang SW, Lu FZ, Mu R, Zhang XD, Huang-Pu XM, Sun J, et al. Research on characteristics of mortality spectrum and type composition of malignant tumors in China. Chin J Oncol 1997;19:323-328. (in Chinese).
4. 4. Lee NW, Wong J, Ong GB. The surgical management of primary carcinoma of the liver. World J Surg 1982;6:66-75.
5. 5. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients. Cancer 1985;56:918-928.
6. 6. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC. Immunohistochemical study of angiogenesis in hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 1999;125:419-426.
7. 7. Brouty-Boye D, Zetter BR. Inhibition of cell motility by Interferon. Science 1980;208:516-518.
8. 8. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987;104:689-696.
9. 9. Maheshwari RK, Srikantan V, Bhartiya D, Kleinman HK, Grant DS. Differential effects of Interferon gamma and alpha on in vitro model of angiogenesis. Cell Physiol 1990;146:164-169.
10. 10. Ruszcak Z, Detmar M, Imcke E, Orfanos CE. Effects of rIFN alpha, beta and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cell in vitro. J Invest Dermatol 1990;95:693-699.
11. 11. Sidky Y, Borden E. Inhibition of angiogenesis by interferons: Effects on tumor and lymphocyte-induced vascular responses. Cancer Res 1987;47: 5155-5161.
12. 12. Singh RK, Gutman M, Bucana CD, Sanchez R, Hansa N, Fidler IJ. Interferons-α and -β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995;92:4562-4566.
13. 13. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon-α-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-1463.
14. 14. Kirn DH, Kramer A. Long-term freedom from disease progression with interferon-α therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst 1996;88:764-765.
15. 15. Tian J, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC) and its expression of the factors associated with metastasis. Br J Cancer 1999;81:814-821.
16. 16. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunological criteria. J Clin Invest 1973;52:2745-2756.
17. 17. Sun FX, Tang ZY, Liu KD, Ye SL, Xue Q, Gao DM, Ma ZC. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 1996;66:239-243.
18. 18. Yang R, Rescorla FJ, Reilly CR, Fanght PR, Sanhvi NT, Lumeng L, Franklin TD Jr, et al. A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation. J Surg Res 1992;52:193-198.
19. 19. Sun HC, Li XM, Xue Q, Chen J, Gao DM, Tang ZY. Study of angiogenesis induced by metastatic and non-metastatic liver cancer by corneal micropocket model in nude mice. World J Gastroenterol 1999;5:116-118.
20. 20. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P, et al. Nitric oxide mediates in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94:2036-2044.
21. 21. Mensing H, Pontz BF, Muller PK, Gauss-Muller V. A study on fibroblast chemotaxis using fibronectin and conditioned medium as chemoattractants. Eur J Cell Biol 1983;29:268-273.
22. 22. Terranova VP. DiFlorio R, Lyall RM, Hic S, Friesel R, Maciag T. Human endothelial cells are chemotactic to endothelial cell growth factor and heparin. J Cell Biol. 1985;101:2330-2334.
23. 23. Okuda K. Primary liver cancers in Japan. Cancer 1980;45:2663-2672.
24. 24. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. HEPATOLOGY 1993;17:389-394.
25. 25. Bokemeyer C, Kynast B, Harstrick A, Laage E, Schmoll E, von Wussow P, Schmoll HJ. No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 1995;35:334-338.
26. 26. Nair PV, Tong MJ, Kempf R, Co R, Lee SD, Venturi CL. Clinical, serologic, and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma. Cancer 1985;56:1018-1022.
27. 27. Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol 1996;19:136-139.
28. 28. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998;55:39-47.
29. 29. Lygidakis NJ, Pothoulakis J, Konstantinidou AE, Spanos H. Hepatocellular carcinoma: Surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 1995;15:543-550.
30. 30. Fabra S, Nakajima M, Bucana CD, Fidler IJ. Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice. Differentiation 1992;52:101-110.
31. 31. Sinkovics JG. Kaposi's sarcoma: Its oncogenes and growth factors. Clin Rev Oncol Hematol 1991;11:87-107.
32. 32. Gutterman JU. Cytokine therapeutics: Lessons from interferon-α. Proc Natl Acad sci USA 1994;91:1198-1205.
33. 33. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
34. 34. Hori A, Sadada R, Masutani E, Naito K, Sakura Y, Fujita T, Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human fibroblast growth factor. Cancer Res 1991;51: 6180-6184.
35. 35. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor cell growth in vivo. Nature 1993;362:841-844.
36. 36. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative F1k-1 mutant. Nature 1994;367:576-578.
37. 37. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1995;79: 315-328.
38. 38. O'Reilly MS, Boehm T, Sing Y, Fukai N, Vasios G, Lane WS, Flynn E, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.